Texas Would Study Psilocybin And MDMA To Treat PTSD And Depression Under New Bill
Marijuana Stocks, Finance, & InvestingUncategorized February 15, 2021 MJ Shareholders
A Texas lawmaker introduced a bill on Wednesday that would require the state to study the therapeutic potential of psilocybin, MDMA and ketamine in the treatment of certain mental health conditions.
The legislation from Rep. Alex Dominguez (D) would mandate that the Department of State Health Services conduct the study in collaboration with the Texas Medical Board and report on its findings by December 1, 2022.
Researchers should “evaluate and determine whether alternative therapies are effective in treating the mental health and other medical conditions” such as depression, anxiety, post-traumatic stress disorder, bipolar disorder, chronic pain and migraines, the text of the bill, HB 1802, states.
Read More
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
